TENX

Business Context and Reporting Period

Company: Oxygen Biotherapeutics, Inc. (formerly Synthetic Blood International, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2008
Business Overview: A development-stage biotechnology company focused on oxygen delivery to tissue. The primary product is Oxycyte™, a perfluorocarbon-based synthetic oxygen carrier intended as an alternative to blood transfusions. Other products in development include Fluorovent™ (lung treatment) and an implanted glucose biosensor, though development on these is currently on hold pending financing or partnerships.
Corporate Action: On June 30, 2008, the company completed a merger to change its state of incorporation from New Jersey to Delaware, adopting the name Oxygen Biotherapeutics, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Improvement: Cash increased from $16,234 to $4.88 million, driven by $6.335 million in proceeds from the sale of convertible debentures and the exchange of short-term bridge loans for five-year convertible notes.
• Increased Losses: Net loss more than doubled to $6.72 million. This was primarily due to a $1.93 million increase in interest charges (including amortization of original issue discounts and warrant values) and a $972,892 increase in G&A expenses (largely due to non-cash stock-based compensation).
• Debt Restructuring: The company exchanged short-term notes for long-term convertible debentures, resulting in a $250,097 debt extinguishment loss and significant non-cash discounts recorded against the new debt.
• Operational Focus: R&D spending increased slightly as the company resumed funding Phase II clinical trials for Oxycyte after a capital shortage in the prior year.

Outlook, Risks, and Management Commentary

• Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. The company requires substantial additional capital to complete clinical trials and regulatory approvals.
• Capital Needs: Management estimates it has sufficient working capital to fund operations through fiscal year 2009. However, additional financing is required by the end of 2009 to cover ongoing testing and administrative expenses. Failure to secure funding could force a cessation of operations.
• Clinical Progress: Phase II-A trials for Oxycyte in severe brain injury patients were completed with good results. A Phase II-B protocol was filed with the FDA in April 2008. Phase III trials are contingent on Phase II results and funding availability.
• Registration Requirement: Warrants totaling approximately 49.4 million shares and convertible notes issued in 2008 require the company to file an effective SEC registration statement by January 9, 2009. Failure to do so could trigger liquidated damages or cash settlement obligations.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including incompatible duties in cash disbursements and insufficient documentation of financing agreements. Remediation plans include hiring a permanent CFO and adding administrative staff.

Investor Verification Checklist

• Financing Timeline: Verify the company's ability to secure additional equity or debt financing before the end of fiscal 2009 to avoid operational cessation.
• Registration Statement: Confirm the status of the SEC registration statement required for the 49.4 million warrants and convertible notes by the January 9, 2009 deadline.
• Dilution Risk: Assess the potential dilution from the conversion of $14+ million in face value of convertible debentures and the exercise of over 125 million outstanding warrants.
• Clinical Milestones: Monitor FDA approval of the Phase II-B protocol and the subsequent results of the severe brain injury trials.
• Internal Controls: Review progress on remediation of material weaknesses, specifically the hiring of a permanent CFO and implementation of segregation of duties.